Aims.This retrospective analysis was aimed at evaluating the effectiveness of treatment of persistent diabetic macular edema with\r\nintravitreal injections of 0.7mg dexamethasone implant Ozurdex. The study comprised three male patients (6 eyes). Results. The\r\naverage thickness of the retina at baseline was 632 �µm, the medial BCVA was 0.8 logMAR, and corrected intraocular pressure\r\nwas 13.7mmHg. The maximum decrease in mean retinal thickness was observed at four weeks following the treatment and was\r\n365 �µm (-267 �µm) and visual acuity improved by an average of two lines and was 0.6 logMAR.The largest increase in mean retinal\r\nthickness to average of 528 �µm (? �µm) occurred at 16 weeks and the average BCVA was 0.614 lines BCVA logMAR. In one eye,\r\nthere was a steroid cataract development after the third dose of dexamethasone implant of 0.7mg. Conclusions. The intravitreal\r\ndexamethasone implant treatment of patients with persistent diabetic macular edema in whom laser photocoagulation proved to\r\nbe ineffective and as a result they required a monthly injection of anti-VEGF factors (Ranibizumab, Bevacizumab) may be a good\r\nalternative to extending the interval of injections. However, reinjections involve a high risk of developing poststeroid cataracts,\r\nwhich is not without significance in middle-aged patients.
Loading....